

Response dated August 4, 2005


Reply to Office action mailed May 6, 2005

Amendments to the Abstract:

Please amend the abstract to read as follows:

ABSTRACT

The use of purine derivatives of formula (I):



in which:

Rx is $-(Z)_n-R_1$ whereinZ is a divalent radical selected from $-CH_2-$, $-SO_2-$, $-CO-$, $-COO-$, $-CONH-$ and $-(CH_2)_2-NR_6-$,

n is the an integer selected from 0 and 1,

R₁ is selected from hydrogen, aryl, $-CH_2$ -aryl, $-SO_2$ -aryl, heterocyclic, $-CH_2$ -heterocyclic, alkyl and $-SO_2$ -alkyl,

Ry is a phenyl radical (optionally substituted) or the radical:

wherein D₁ and D₂, which are identical or different, are selected from hydrogen, hydroxyl, the linear or branched alkyl or alkoxy radicals containing at most 6 carbon atoms and NHR_5 , or, alternatively, taken together, D₁ and D₂ form a radical selected from $=O$ and $=N-OR_4$,R₄ is hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl or aryl,R₅ is hydrogen, alkyl, cycloalkyl, or $-COOtBu$ (Boc), andR₆ is hydrogen, alkyl or cycloalkyl, wherein the alkyl moiety contains 1 to 6, optionally substituted, carbon atoms;

as cdk kinase inhibitors for the prevention and treatment of fungal infections. Also disclosed are novel methods and intermediates for the production of compounds of formula I, as well as pharmaceutical compositions containing said compounds.